Table 2 Adverse events of first-line EGFR-TKIs.

From: Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs

Variables

All (N = 138)

MINO + (N = 32)

MINO – (N = 106)

P value

Skin rash

88 (63.8)

27 (84.4)

61 (57.5)

0.0062

Hepatic dysfunction

31 (22.5)

9 (28.1)

22 (20.8)

0.47

Gastrointestinal toxicity

31 (22.5)

14 (43.8)

17 (16.0)

0.0029

Renal dysfunction

3 (2.2)

1 (3.1)

2 (1.9)

1.0

Lung injury

2 (1.4)

0 (0)

2 (1.9)

1.0

Heart failure

2 (1.4)

1 (0)

1 (1.9)

0.41

Neutropenia

1 (0.72)

0 (0)

1 (1.9)

1.0

Neuropathy

1 (0.72)

0 (0)

1 (1.9)

1.0

  1. Data are presented as N (%).
  2. MINO minocycline, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor.
Back to article page